Profile Response Detail

Molecular Profile Unknown unknown
Therapy Utomilumab
Indication/Tumor Type Merkel cell carcinoma
Response Type not applicable
Create By tyin
Update By tyin

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Merkel cell carcinoma not applicable Utomilumab Phase I Actionable In a Phase I trial, Utomilumab (PF-05082566) treatment resulted in an overall objective response rate of 13.3% (2/15, 1 complete response, 1 partial response) in patients with Merkel cell carcinoma (PMID: 29549159; NCT01307267). 29549159
PubMed Id Reference Title Details
(29549159) Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Full reference...